Search bioRxiv⌕ Search

Biology subjects

Lochmüller, H.

Publications and source records attributed to Lochmüller, H..

2 recordsLinked to original sources

Cell-type-specific adaptations to mitochondrial stress underly the neurological presentations of MTRFR mutations

Mitochondrial diseases are a group of heterogeneous genetic disorders that exhibit striking tissue specificity. Neurological involvement is among the most consistent features, yet the mechanisms that determine why selective neuronal populations are particularly vulnerable to mitochondrial dysfunction remain poorly understood. Mutations in MTRFR, a mitochondrial ribosome rescue factor, cause a progressive neuromuscular phenotype, but no relevant disease model exists to explain its cell-type-specific pathology. Here, we established the first human iPSC-derived neuronal model of MTRFR loss and identified mechanisms driving differential vulnerability between cortical and motor neurons. Although knockdown led to comparable deficits in mitochondrial translation and OXPHOS across both subtypes, cortical neurons engaged adaptive programs, including dendritic mitochondrial remodelling and heat-shock response activation, that preserved survival. Motor neurons failed to mount these responses and instead displayed apoptotic and inflammatory priming. Pharmacological enhancement of stress adaptation rescued motor neuron survival, indicating that resilience is programmable. These findings provide the first mechanistic evidence that neuronal susceptibility to mitochondrial translation defects is defined by the capacity to activate mitochondrial and cytoprotective stress-response pathways.

neuroscience↗

Gene-specific response to MuSK agonist antibody in the treatment of Congenital Myasthenic Syndromes

Congenital myasthenic syndromes (CMS) are a group of rare disorders characterized by fatigable muscle weakness and caused by impaired neuromuscular junction (NMJ) function. CMS symptoms are highly variable, but can be detrimental and lead to death. There are over 40 different genetic subtypes, including Agrn-CMS and ColQ-CMS. Agrn encodes for neural AGRIN, which is released from the nerve terminal and triggers muscle-specific kinase phosphorylation (pMuSK). pMuSK is essential for NMJ development and maintenance, thus AGRIN deficiency causes NMJ impairment. ColQ encodes for collagenous subunit Q (ColQ), which anchors acetylcholinesterase and stabilizes MuSK. As a result, ColQ deficiency results in NMJ degeneration from prolonged transmission signals and decreased pMuSK. Current treatments for Agrn-CMS and ColQ-CMS are limited, highlighting the importance of finding more efficient therapies. Recently, a MuSK agonist antibody with high affinity for the Frizzled-like domain showed remarkable rescue of a Dok7-CMS mouse model. We hypothesized a similar antibody could benefit Agrn- and ColQ-CMS mouse models. Agrn-CMS mice were treated at postnatal day 5 (P5), P15 and P35, and ColQ-CMS mice were treated weekly from P22 to P57. In Agrn-CMS mice, 3B2 treatment rescued survival, bodyweight, fibre type switching and pMuSK levels, and improved grip strength and NMJ morphology. In ColQ-CMS mice, 3B2 treatment was unable to rescue deficits observed. Our findings suggest that MuSK agonists may benefit patients with Agrn-CMS, which should be tested in clinical trials. Our study emphasizes that effective CMS treatment is gene-dependent and relies on an accurate genetic diagnosis.

molecular biology↗